IB and Prism Secure First Installation

Imaging Biometrics (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the successful first installation of its bundled technologies in partnership with Prism Clinical Imaging, Inc. (Prism), at a major Southeastern US health system. Prism, recognized for its expertise in brain mapping software and applications, and IB, a leading provider of quantitative imaging solutions, have collaborated to deliver advanced tools that support the diagnosis of brain diseases and improve treatment planning. This marks the first installation under the partnership between Prism and IB. The integrated technologies combine brain mapping and analysis tools for clinical use in diagnosing brain disease and guiding treatment.

The comprehensive suite of tools offered by IB and Prism help clinicians treat brain tumor patients by identifying structures to avoid when navigating to a tumor site (Prism) and, once there, distinguishing between aggressive tumor and non-tumor tissue (IB) to aid biopsy and tumor resection planning. By providing detailed images of brain activity and tumor physiology, the combined technologies allow neurosurgeons to plan the safest and optimal surgical approach while preserving functions like speech, movement, and sight. The goal is to keep post-operative defects to a minimum and maximize overall prognosis.

Functional magnetic resonance imaging (fMRI) is experiencing growth driven by the increasing prevalence of neurological disorders and the rising demand of diagnostic tools. The advanced technologies offered by Prism and IB are cutting-edge solutions for healthcare providers which can enhance patient care and clinical outcomes.

The Directors of the Company accept responsibility for the contents of this announcement.